Incyte PT receives Investment Bank Analyst Rating Update
- ByInvesting.com-
Symbol | Exchange | Currency |
|---|
Incyte (INCY) reported Q4 EPS of $0.62, $0.32 better than the analyst estimate of $0.30. Revenue for the quarter came in at $926.7 million versus the consensus estimate of $878.16...
Investing.com - Incyte (NASDAQ: INCY) reported fourth quarter EPS of $0.62, $0.32 better than the analyst estimate of $0.30. Revenue for the quarter came in at $926.7M versus the...
The market jumped on Powell's dovish comments and soft CPI reading in November However, there's been little follow-through on that rally as investors await further clues from the...
AbbVie ABBV has submitted regulatory applications to the FDA and European Medicines Agency (EMA) seeking approval of its JAK inhibitor drug, Rinvoq (upadacitinib) for the treatment...
Executive Summary Shareholder meetings and conferences ramp up after a busy summer and ahead of the next earnings season The Delta variant forced many companies to quickly switch...
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland, and Japanese office in Tokyo and Canadian headquarters in Montreal. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Neutral | Sell | Sell | Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Sell | Strong Sell | Strong Buy |
| Summary | Strong Buy | Buy | Strong Sell | Strong Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 62.13 | 62.38 | 59.70 | +2.15 | +3.58% | 12.70M | NASDAQ | |||
| 154.65 | 155.23 | 150.64 | +2.92 | +1.92% | 82.97M | NASDAQ | |||
| 102.00 | 102.41 | 98.08 | -0.18 | -0.18% | 115.86M | NASDAQ | |||
| 196.81 | 197.50 | 189.55 | +2.05 | +1.05% | 185.07M | NASDAQ | |||
| 362.95 | 364.18 | 354.18 | +1.47 | +0.41% | 6.25M | NASDAQ | |||
| 267.56 | 268.77 | 260.08 | +10.79 | +4.20% | 50.36M | NASDAQ | |||
| 191.62 | 193.78 | 184.40 | +5.56 | +2.99% | 45.68M | NASDAQ | |||
| 173.70 | 173.93 | 171.02 | +1.20 | +0.70% | 434.07K | NASDAQ | |||
| 87.74 | 88.02 | 86.30 | -0.79 | -0.89% | 8.98M | NYSE | |||
| 0.10 | 0.10 | 0.07 | 0.00 | 0.00% | 0.00 | OTC Markets | |||
| 7.61 | 7.79 | 7.51 | -0.04 | -0.52% | 5.42M | NYSE | |||
| 0.40 | 0.40 | 0.40 | 0.00 | 0.00% | 0.00 | OTC Markets | |||
| 9.31 | 9.64 | 8.62 | -0.28 | -2.92% | 193.63K | NASDAQ | |||
| 64.60 | 64.69 | 61.80 | +3.05 | +4.96% | 12.89M | NYSE | |||
| 5.95 | 6.05 | 5.71 | +0.01 | +0.17% | 10.95M | NYSE |